Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Multiple Sclerosis

  Free Subscription


09.09.2019

1 Ann Neurol
1 Arch Phys Med Rehabil
1 Int J Neurosci
1 J Neurol
1 J Neurol Sci
1 J Neurosci Res
3 Lancet Neurol
1 Mult Scler
1 Nat Rev Neurol
2 Neurology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. KRYSKO KM, Henry RG, Cree BAC, Lin J, et al
    Telomere length is associated with disability progression in multiple sclerosis.
    Ann Neurol. 2019 Sep 4. doi: 10.1002/ana.25592.
    PubMed     Text format     Abstract available


    Arch Phys Med Rehabil

  2. BURGGRAAFF J, Dorn J, D Souza M, Morrison C, et al
    Video-based pairwise comparison: enabling the development of automated rating of motor dysfunction in multiple sclerosis.
    Arch Phys Med Rehabil. 2019 Aug 29. pii: S0003-9993(19)31047.
    PubMed     Text format     Abstract available


    Int J Neurosci

  3. EFTEKHARIAN MM, Taheri M, Arsang-Jang S, Komaki A, et al
    Nicotinamide nucleotide transhydrogenase expression analysis in multiple sclerosis patients.
    Int J Neurosci. 2019 Sep 2:1-5. doi: 10.1080/00207454.2019.1660655.
    PubMed     Text format     Abstract available


    J Neurol

  4. SHEMA-SHIRATZKY S, Gazit E, Sun R, Regev K, et al
    Deterioration of specific aspects of gait during the instrumented 6-min walk test among people with multiple sclerosis.
    J Neurol. 2019 Sep 6. pii: 10.1007/s00415-019-09500.
    PubMed     Text format     Abstract available


    J Neurol Sci

  5. NOHARA S, Ishii A, Yamamoto F, Yanagiha K, et al
    GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis.
    J Neurol Sci. 2019;405:116429.
    PubMed     Text format     Abstract available


    J Neurosci Res

  6. GUO LY, Lozinski B, Yong VW
    Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes.
    J Neurosci Res. 2019 Sep 4. doi: 10.1002/jnr.24524.
    PubMed     Text format     Abstract available


    Lancet Neurol

  7. MOWRY EM, Corboy JR
    Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis.
    Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30333.
    PubMed     Text format    

  8. COMI G, Kappos L, Selmaj KW, Bar-Or A, et al
    Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30239.
    PubMed     Text format     Abstract available

  9. COHEN JA, Comi G, Selmaj KW, Bar-Or A, et al
    Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30238.
    PubMed     Text format     Abstract available


    Mult Scler

  10. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  11. LEMPRIERE S
    The central vein sign as a clinical diagnostic biomarker for multiple sclerosis.
    Nat Rev Neurol. 2019 Sep 4. pii: 10.1038/s41582-019-0261.
    PubMed     Text format    


    Neurology

  12. EIJLERS AJC, Dekker I, Steenwijk MD, Meijer KA, et al
    Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008198.
    PubMed     Text format     Abstract available

  13. BARKHOF F, Kappos L, Wolinsky JS, Li DKB, et al
    Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008189.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: